HALO  valuation analysis

Basics
Name: Halozyme Therapeutics, Inc
Description: Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 10, 2021
Market cap: $6.15B (642nd)
Sales(TTM): $331.26M (1287th)
Earnings(TTM): $163.08M (702nd)

Value
FFER: 2.14*
Actual price: $42.90
* Earnings were reported Aug 09, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-07-15
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • Halozyme Therapeutics, Inc's earnings increased from -$80.14M to $163.08M in the last year.
  • Halozyme Therapeutics, Inc's operating income increased from -$73.80M to $198.21M in the last year.
Earnings / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Sales / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Book / MarketCap
Halozyme Therapeutics, Inc
"Biotechnology" industry
Equity / Assets
Halozyme Therapeutics, Inc
"Biotechnology" industry